Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshihiro Noguchi

Showing results (1-10 of 162) with videos related to

Pageof 17
Sort By:
Drug Safety|June 17, 2022
Comment on: "Drug-Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data"Yoshihiro Noguchi
Drug Safety|October 12, 2022
Comment on: "A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)"Yoshihiro Noguchi
Pharmacoepidemiology and Drug Safety|November 20, 2023
Is it possible to identify risk factors for adverse drug reactions using a pharmacovigilance database based on spontaneous reporting?Yoshihiro Noguchi, Tomoaki Yoshimura
European Journal of Pediatrics|December 4, 2023
Comment on: "Drug-associated kidney injury in children: a disproportionality analysis of the FDA adverse event reporting system"Yoshihiro Noguchi, Tomoaki Yoshimura
Pharmacoepidemiology and Drug Safety|November 10, 2023
Comment on: Exploring the impact of design criteria for reference sets on performance evaluation of signal detection algorithms: The case of drug-drug interactionsYoshihiro Noguchi, Tomoaki Yoshimura
International Journal of Cancer|March 9, 2023
Comment on: "Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis"Yoshihiro Noguchi, Miao Yan
Journal of the European Academy of Dermatology and Venereology : JEADV|July 2, 2024
Comment on: 'Drugs associated with epidermal necrolysis in children: A World Health Organization pharmacovigilance database analysis'Yoshihiro Noguchi, Tomoaki Yoshimura
Journal of Clinical Pharmacology|July 28, 2023
Comment: Detection of Vaccine Adverse Events Before Package Insert Revisions Using a Japanese Spontaneous Reporting SystemYoshihiro Noguchi, Tomoaki Yoshimura
Expert Opinion on Drug Safety|October 13, 2025
Letter to the Editor in response to: "Drug-induced noninfectious myocarditis: a disproportionality analysis of the FAERS database"Shuang Xia, Yoshihiro Noguchi
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|July 21, 2024
Are demographic findings really possible from reports in a spontaneous reporting system?Yoshihiro Noguchi, Tomoaki Yoshimura
Pageof 17

Showing results (1-10 of 162) with videos related to

Sort By:
Pageof 17
Drug Safety|June 17, 2022
Comment on: "Drug-Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data"Yoshihiro Noguchi
Drug Safety|October 12, 2022
Comment on: "A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)"Yoshihiro Noguchi
Pharmacoepidemiology and Drug Safety|November 20, 2023
Is it possible to identify risk factors for adverse drug reactions using a pharmacovigilance database based on spontaneous reporting?Yoshihiro Noguchi, Tomoaki Yoshimura
European Journal of Pediatrics|December 4, 2023
Comment on: "Drug-associated kidney injury in children: a disproportionality analysis of the FDA adverse event reporting system"Yoshihiro Noguchi, Tomoaki Yoshimura
Pharmacoepidemiology and Drug Safety|November 10, 2023
Comment on: Exploring the impact of design criteria for reference sets on performance evaluation of signal detection algorithms: The case of drug-drug interactionsYoshihiro Noguchi, Tomoaki Yoshimura
International Journal of Cancer|March 9, 2023
Comment on: "Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis"Yoshihiro Noguchi, Miao Yan
Journal of the European Academy of Dermatology and Venereology : JEADV|July 2, 2024
Comment on: 'Drugs associated with epidermal necrolysis in children: A World Health Organization pharmacovigilance database analysis'Yoshihiro Noguchi, Tomoaki Yoshimura
Journal of Clinical Pharmacology|July 28, 2023
Comment: Detection of Vaccine Adverse Events Before Package Insert Revisions Using a Japanese Spontaneous Reporting SystemYoshihiro Noguchi, Tomoaki Yoshimura
Expert Opinion on Drug Safety|October 13, 2025
Letter to the Editor in response to: "Drug-induced noninfectious myocarditis: a disproportionality analysis of the FAERS database"Shuang Xia, Yoshihiro Noguchi
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|July 21, 2024
Are demographic findings really possible from reports in a spontaneous reporting system?Yoshihiro Noguchi, Tomoaki Yoshimura
Pageof 17